3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
4
lanreotide
4
Sunitinib
4
Temozolomide
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Capecitabine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Quality of Life
2
FAPI-46
2
veliparib
1
tivozanib
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pasireotide
1
gallium Ga 68 dotatate
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Gastrointestinal
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled